FAM110B

Across TCGA pan-cancer cohorts, FAM110B Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated FAM110B data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher FAM110B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM110B expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

READ, KIRP, and LIHC are the cancer types where FAM110B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	32	view →
KIRP	OS	Median	II,III,IV	0.132	0.772	<.001	26	view →
LIHC	OS	Median	All	0.142	0.709	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.944	0.300	.003	24	view →
ESCA	OS	Median	III,IV	0.108	0.574	<.001	12	view →
BLCA	OS	Median	IV	0.137	0.604	<.001	12	view →
SARC	DFS	Median	All	0.158	0.613	.005	6	view →
SKCM	DFS	Median	II,III,IV	0.046	0.708	<.001	6	view →
BRCA	DFS	Median	All	0.562	0.949	.018	4	view →
LUSC	DFS	Median	II,III,IV	1.000	0.379	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

FAM110B–READ (OS)

Open the READ breakdown →